Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Leslie B Epling

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Nature Communications|July 17, 2019
DNA translocation mechanism of the MCM complex and implications for replication initiationMartin Meagher, Leslie B Epling, Eric J Enemark
Elife|September 30, 2014
Analysis of the crystal structure of an active MCM hexamerJustin M Miller, Buenafe T Arachea, Leslie B Epling, et al.
Elife|April 3, 2014
A conserved MCM single-stranded DNA binding element is essential for replication initiationClifford A Froelich, Sukhyun Kang, Leslie B Epling, et al.
Journal of Molecular Biology|March 1, 2015
Cancer-associated mutants of RNA helicase DDX3X are defective in RNA-stimulated ATP hydrolysisLeslie B Epling, Christy R Grace, Brandon R Lowe, et al.
Journal of Medicinal Chemistry|February 7, 2024
Discovery of (4-Pyrazolyl)-2-aminopyrimidines as Potent and Selective Inhibitors of Cyclin-Dependent Kinase 2Joshua R Hummel, Kai-Jiong Xiao, Jeffrey C Yang, et al.
Journal of Medicinal Chemistry|November 10, 2022
Discovery of Potent and Selective Inhibitors of Wild-Type and Gatekeeper Mutant Fibroblast Growth Factor Receptor (FGFR) 2/3Artem Shvartsbart, Jeremy J Roach, Michael R Witten, et al.
ACS Medicinal Chemistry Letters|March 18, 2026
Discovery of a Selective and Potent Inhibitor of Cyclin-Dependent Kinase 12/13 Employing a Noncovalent MechanismRobert A Swyka, Evan D Styduhar, Anlai Wang, et al.
Journal of Medicinal Chemistry|May 27, 2026
Discovery of the Orally Bioavailable Isoform Selective Janus Kinase 1 (JAK1) Compound Povorcitinib (INCB054707) for the Treatment of Inflammatory and Autoimmune DiseasesJincong Zhuo, Yun-Long Li, Ding-Quan Qian, et al.
Journal of Medicinal Chemistry|January 8, 2025
Discovery of INCB159020, an Orally Bioavailable KRAS G12D InhibitorQinda Ye, Artem Shvartsbart, Zhenwu Li, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Nature Communications|July 17, 2019
DNA translocation mechanism of the MCM complex and implications for replication initiationMartin Meagher, Leslie B Epling, Eric J Enemark
Elife|September 30, 2014
Analysis of the crystal structure of an active MCM hexamerJustin M Miller, Buenafe T Arachea, Leslie B Epling, et al.
Elife|April 3, 2014
A conserved MCM single-stranded DNA binding element is essential for replication initiationClifford A Froelich, Sukhyun Kang, Leslie B Epling, et al.
Journal of Molecular Biology|March 1, 2015
Cancer-associated mutants of RNA helicase DDX3X are defective in RNA-stimulated ATP hydrolysisLeslie B Epling, Christy R Grace, Brandon R Lowe, et al.
Journal of Medicinal Chemistry|February 7, 2024
Discovery of (4-Pyrazolyl)-2-aminopyrimidines as Potent and Selective Inhibitors of Cyclin-Dependent Kinase 2Joshua R Hummel, Kai-Jiong Xiao, Jeffrey C Yang, et al.
Journal of Medicinal Chemistry|November 10, 2022
Discovery of Potent and Selective Inhibitors of Wild-Type and Gatekeeper Mutant Fibroblast Growth Factor Receptor (FGFR) 2/3Artem Shvartsbart, Jeremy J Roach, Michael R Witten, et al.
ACS Medicinal Chemistry Letters|March 18, 2026
Discovery of a Selective and Potent Inhibitor of Cyclin-Dependent Kinase 12/13 Employing a Noncovalent MechanismRobert A Swyka, Evan D Styduhar, Anlai Wang, et al.
Journal of Medicinal Chemistry|May 27, 2026
Discovery of the Orally Bioavailable Isoform Selective Janus Kinase 1 (JAK1) Compound Povorcitinib (INCB054707) for the Treatment of Inflammatory and Autoimmune DiseasesJincong Zhuo, Yun-Long Li, Ding-Quan Qian, et al.
Journal of Medicinal Chemistry|January 8, 2025
Discovery of INCB159020, an Orally Bioavailable KRAS G12D InhibitorQinda Ye, Artem Shvartsbart, Zhenwu Li, et al.
Pageof 1